Literature DB >> 10893688

Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures.

A Oleksik1, P Lips, A Dawson, M E Minshall, W Shen, C Cooper, J Kanis.   

Abstract

Fractures and subsequent morbidity determine the impact of established postmenopausal osteoporosis. Health-related quality of life (HRQOL) has become an important outcome criterion in the assessment and follow-up of osteoporotic patients. As part of the baseline measurements of the Multiple Outcomes of Raloxifene Evaluation (MORE) study, HRQOL was assessed in 751 osteoporotic (bone mineral density [BMD] T score > or = -2.5) women from Europe with or without vertebral fractures (VFX). This was done using the quality of life questionnaire of the European Foundation for Osteoporosis (QUALEFFO), Nottingham Health Profile (NHP) and the EQ-5D (former EuroQol). QUALEFFO contains questions in five domains: pain, physical function, social function, general health perception, and mental function. Each domain score and QUALEFFO total scores are expressed on a 100-point scale, with 0 corresponding to the best HRQOL. In comparison with patients without VFX, those with VFX were older (66.2 +/- 5.9 years vs. 68.8 +/- 6.3 years; p < 0.001), had higher prevalence of nonvertebral fractures (25% vs. 36%; p = 0.002), and higher QUALEFFO scores (worse HRQOL; total score, 26 +/- 14 vs. 36 +/- 17; p < 0.001). QUALEFFO scores increased progressively with increasing number of VFX, especially lumbar fractures (p < 0.001). Patients with a single VFX already had a significant increase in QUALEFFO scores (p < 0.05). Similar, though weaker, associations were seen for NHP and EQ-5D scores. This study confirms decreased HRQOL for patients with prevalent VFX. In osteoporotic patients, QUALEFFO scores change in relation to the number of VFX. QUALEFFO is suitable for clinical studies in patients with postmenopausal osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10893688     DOI: 10.1359/jbmr.2000.15.7.1384

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  183 in total

1.  Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women.

Authors:  Smita Nayak; Mark S Roberts; Susan L Greenspan
Journal:  Ann Intern Med       Date:  2011-12-06       Impact factor: 25.391

2.  Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective.

Authors:  F Borgström; O Ström; M Kleman; E McCloskey; H Johansson; A Odén; J A Kanis
Journal:  Osteoporos Int       Date:  2010-06-08       Impact factor: 4.507

3.  Familial correlation of bone mineral density, birth data and lifestyle factors among adolescent daughters, mothers and grandmothers.

Authors:  Hiroaki Ohta; Tatsuhiko Kuroda; Yoshiko Onoe; Chie Nakano; Remi Yoshikata; Ken Ishitani; Kazunori Hashimoto; Miyoko Kume
Journal:  J Bone Miner Metab       Date:  2010-04-21       Impact factor: 2.626

4.  Short-term menatetrenone therapy increases gamma-carboxylation of osteocalcin with a moderate increase of bone turnover in postmenopausal osteoporosis: a randomized prospective study.

Authors:  Masataka Shiraki; Akira Itabashi
Journal:  J Bone Miner Metab       Date:  2009-01-27       Impact factor: 2.626

5.  Impact of vertebral deformities, osteoarthritis, and other chronic diseases on quality of life: a population-based study.

Authors:  N M van Schoor; J H Smit; J W R Twisk; P Lips
Journal:  Osteoporos Int       Date:  2004-10-12       Impact factor: 4.507

Review 6.  Clinical effects of strontium ranelate in women with postmenopausal osteoporosis.

Authors:  Pierre D Delmas
Journal:  Osteoporos Int       Date:  2005-01       Impact factor: 4.507

7.  Cross-geographic region differences in quality of life in women with and without vertebral fracture.

Authors:  N M van Schoor; H Yu; J Bobula; P Lips
Journal:  Osteoporos Int       Date:  2009-02-24       Impact factor: 4.507

Review 8.  The epidemiology of osteoporosis.

Authors:  Michael A Clynes; Nicholas C Harvey; Elizabeth M Curtis; Nicholas R Fuggle; Elaine M Dennison; Cyrus Cooper
Journal:  Br Med Bull       Date:  2020-05-15       Impact factor: 4.291

9.  The risk and burden of vertebral fractures in Sweden.

Authors:  J A Kanis; O Johnell; A Oden; F Borgstrom; N Zethraeus; C De Laet; B Jonsson
Journal:  Osteoporos Int       Date:  2003-10-31       Impact factor: 4.507

10.  Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) trial.

Authors:  Tetsuo Nakano; Masataka Shiraki; Toshitsugu Sugimoto; Hideaki Kishimoto; Masako Ito; Masao Fukunaga; Hiroshi Hagino; Teruki Sone; Tatsuhiko Kuroda; Toshitaka Nakamura
Journal:  J Bone Miner Metab       Date:  2013-11-09       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.